To date, therapies that target the angiogenic nature of the tumor, such as the use of monoclonal antibodies for Vascular Endothelial Growth Factor (VEGF) (Bevacizumab), have displayed some promising results in the clinical trials (5). Here, VEGFA is linked to neoplasm.